Molekularne mechanizmy onkogenezy wirusowej u ludzi i zwierząt

• Autorzy: Wojtala A. , Niemialtowski M.

Warianty tytułu

EN

Molecular mechanisms of viral oncogenesis in humans and animals

• Języki publikacji: PL

Abstrakty

EN

Tumors are one of the most important health problems for man and animals in the context of human health protection and food hygiene. It is well known that cancer diseases depend on genetic background and subtle molecular regulation of cell division and can be induced by three groups of carcinogens: biological (i.e. some viruses known as oncogenic viruses), physical and chemical. To date more than 50 various DNA (i.e. herpesviruses, adenoviruses, papillomaviriruses and polyomaviriruses) and RNA (retroviruses) viruses have been well documented as oncogenic viruses. Viruses (i.e. oncogenic herpesviruses and retroviruses) have evolved long-term survival strategies (latency) in the infected host. In the 1970s oncogen v-src of Rous sarcoma virus (RSV) were identified as a factor that can transform the cells of an infected host. At present we know more than 100 viral oncogens (v-jun) and antioncogens (tumor-supressor genes), that compete in cancer induction or supression, respectively. In contrast normal growth promoting genes (the host genes termed protooncogens, c-jun: i.e. growth factors, growth factor receptors and transcriptional factors) have been identified. Thus viral carcinogens can trigger oncogenesis by indirect (i.e. induction of immunosupression in the case of Kaposis’s sarcoma in HIV⁺/AIDS⁺ patients or by modification of host cell genome) or direct (i.e. altering the expression of host cell proteins at the point of viral DNA integration) mechanisms. Different molecular models of the replication of DNA and RNA viruses are essential for oncogenesis development in the infected cells and can influence the frequency of cancer induction. In contrast to RNA viral carcinogens DNA viruses are less efficient in tumor induction because the progeny of RNA viruses are continually being released from the virally transformed cells. In this paper the molecular mechanisms of viral oncogenesis in the context of human (EBV, HPV, HCV, HTLV-1) or animal (RSV, AMV, MDV) viruses is briefly described and discussed.

Słowa kluczowe

PL

choroby czlowieka; choroby zwierzat; mechanizmy molekularne; nowotwory; onkogeneza; wirus Epsteina-Barr; wirus HPV; wirus HTLV-1; wirus choroby Mareka; wirus ptasiej mieloblastozy; wirus zapalenia watroby typu C; wirusy onkogenne; wlasciwosci

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2010
• Tom: 66
• Numer: 12
• Opis fizyczny: s.810-817,rys.,tab.,bibliogr.

Twórcy

autor

Wojtala A.

• Zakład Immunologii, Katedra Nauk Przedklinicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego, ul.Ciszewskiego 8, 02-786 Warszawa

autor

Niemialtowski M.

Bibliografia

• 1.Andersson K. B., Kowenz-Leutz E., Brendeford E. M., Tygsett A. H., Leutz A., Gabrielsen O. S.: Phosphorylation-dependent down-regulation of c-Myb DNA binding is abrogated by a point mutation in the v-myb oncogene. J. Biol. Chem. 2003, 278, 3816-3824.
• 2.Barmak K., Haraj E., Grant Ch., Alefantis T., Wigdahl B.: Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology 2003, 308, 1-12.
• 3.Bienias J., Krzemień S., Mazurek U.: Charakterystyka wirusa Epsteina-Barr - aspekty epidemiologiczne, bimolekularne i transplantologiczne. Post. Mikrobiol. 2007, 46, 153-165.
• 4.Biggs P. M.: Marek's disease herpesvirus: oncogenesis and prevention. The Leeuwenhoek Lecture 1997, 352, 1951-1962.
• 5.Blacklow N. R.: Viruses, [w:] Gorbach S. L., Bartlett J. G., Blacklow N. R. (wyd.): Infectious Diseases. 3rd Ed. Lippincott Williams&Wilkins, Philadelphia 2006, 1891-2165.
• 6.Bonneez W.: Human papillomavirus vaccine - recent results and future developments. Curr. Opin. Pharmacol. 2007, 7, 470-477.
• 7.Burk O., Mink S., Ringwald M., Klempnauer K. H.: Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors. J. EMBO 1993, 12, 2027-2038.
• 8.Czepiel J., Biesiada G., Mach T.: Wirusowe zapalenie wątroby typu C. Pol. Arch. Med. Wewn. 2008, 118, 734-740.
• 9.Damania B.: DNA tumor viruses and human cancer. Trends Microbiol. 2007, 15, 38-44.
• 10.Dehbi M., Mbiguino A., Beauchemin M., Gilles C. G., Bedar P. A.: Transcriptional activation of the CEF-4/9E3 cytokine gene by pp60v-src. Mol. Cel. Biol. 1992, 12, 1490-1499.
• 11.Di Bisceglie A. M.: Hepatitis C and Hepatocellular Carcinoma. Hepatology 1997, 26 (Suppl. 1), 35-37.
• 12.Dobrzańska J., Sawczuk-Chabin J., Warzocha K.: Rola wirusów w etiopatogenezie chłoniaków nieziarniczych. Onkol. Prakt. Klin. 2006, 2, 64-72.
• 13.Ferreira Jr. O. C., Planelles V., Rosenblatt D.: Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Rev. 1997, 11, 91-104.
• 14.Howie H. L., Katzenellenbogen R. A., Galloway D. A.: Papillomavirus E6 proteins. Virology 2009, 384, 324-334.
• 15.Kasprzak A., Adamek A.: Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol. Res. 2008, 38, 1-26.
• 16.Król K., Samorek-Salamonowicz E., Kozdruñ W.: Molekularna charakterystyka genów i białek wirusa Mareka. Post. Mikrobiol. 2005, 44, 351-356.
• 17.Liao J. B.: Viruses and Human Cancer. Yale J. Biol. Med. 2006, 79, 115-122.
• 18.Lipsick J. S., Wang D.-M.: Transformation by v-Myb. Oncogene 1999, 18, 3047-3055.
• 19.Masker K., Golden A., Gaffney C. J., Mazack V., Schwindinger W. F., Zhang W., Lu-Hai Wang L.-H., Carey D. J., Sudol M.: Transcriptional profile of Rous Sarcoma virus transformed chicken embryo fibroblasts reveals new signaling targets of viral src. Virology 2007, 364, 10-20.
• 20.McLaughlin-Drubin M. E., Münger K.: The human papillomavirus E7 oncoprotein. Virology 2009, 384, 335-344.
• 21.Mikołajczyk K., Żaba R.: Zakażenia HPV jako problem kliniczny. Przew. Lek. 2005, 5, 38-47.
• 22.Mueller N.: Owerview: Viral Agents and Cancer. Environ. Health Perspect. 1995, 103 (Suppl. 8), 259-261.
• 23.Perbal B.: Avian myeloblastosis virus (AMV): only one side of the coin. Retrovirology 2008, 5, 49-53.
• 24.Samorek-Salamonowicz E.: Choroba Mareka - wybrane zagadnienia. Medycyna Wet. 2009, 65, 812-816.
• 25.Smith M. R., Greene W. C.: Molecular Biology of the Type I Human T-Cell Leukemia Virus (HTLV-I) and Adult T-Cell Leukemia. J. Clin. Invest. 1991, 87, 761-766.
• 26.Szkaradkiewicz A.: Drobnoustroje i onkogeneza. Współ. Onkol. 2003, 7, 96-101.
• 27.Takatsuki K.: Adult T-cell Leukemia. Intern.Med. 1995, 34, 947-952.
• 28.Vogt P. K.: Cancer genes. Wes. J. Med. 1993, 158, 273-278.
• 29.Waris G., Siddiqui A.: Regulatory mechanisms of viral hepatitis B and C. J. Biosci. 2003, 28, 311-321.
• 30.Wensing B., Farrell P. J.: Regulation of cell growth and death by Epstein-Barr virus. Microb. Infect. 2000, 2, 77-84.
• 31.Xie Q., Anderson A. S., Morgan R. W.: Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCCMSB1 MDV-transformed lymphoblastoid cells. J. Virol. 1996, 70, 1125-1131.
• 32.Young L. S., Murray P. G.: Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003, 22, 5108-5121.
• 33.Zimmer C.: Evolved for cancer. Sci. Am. Special. 2008, 18, 15-21.
• 34.zur Hausen H.: Oncogenic DNA viruses. Oncogene 2001, 20, 7820-7823.
• 35.zur Hausen H.: Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis. J. Natl. Cancer Inst. 2000, 92, 690-698.
• 36.zur Hausen H.: Viruses in Human Cancers. Eur. J. Cancer. 1999, 35, 1878-1885.